Kenzaburo Yamaji, Sadahiro Iwabuchi, Yuko Tokunaga, Shinichi Hashimoto, Daisuke Yamane, Sakiko Toyama, Risa Kono, Bouchra Kitab, Kyoko Tsukishima-Kohara, Yosuke Osawa, Yukiko Hayashi, Tsunekazu Hishima, Chise Tateno, Kiminori Kimura, Takeshi Okanoue, Michinori Kohara
Nonalcoholic steatohepatitis (NASH) is a progressive fibrotic disease associated with an increased risk of developing hepatocellular carcinoma; at present, no efficient therapeutic strategy has been established. Herein, we examined the efficacy of PRI-724, a potent inhibitor of CBP/β-catenin signaling, for treating NASH-related liver fibrosis and disorder and characterized its mechanism. Choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-fed mice exhibited NASH-induced liver fibrosis that is characterized by steatosis, lobular inflammation, hepatocellular injury and collagen fibrils...
August 28, 2023: Biomedicine & Pharmacotherapy